Abstract:The substantial progress made in basic sciences of the brain has yet to be adequately translated to successful clinical therapeutics to treat central nervous system (CNS) diseases. Possible explanations include the lack of quantitative and validated biomarkers, the subjective nature of many clinical endpoints, and complex pharmacokinetic/pharmacodynamic (PK/PD) relationships, but also the possibility that highly selective drugs in the CNS do not reflect the complex interactions of different brain circuits. While computational systems pharmacology modeling designed to capture essential components of complex biological systems has been increasingly accepted in pharmaceutical Research & Development (R&D) for oncology, inflammation, and metabolic disorders, the uptake in the CNS field has been very modest. In this paper, a cross‐disciplinary group with representatives from academia, pharma, regulatory and funding agencies make the case that the identification and exploitation of CNS therapeutic targets for drug discovery and development can benefit greatly from a system and network approach that can span the gap between molecular pathways and the neuronal circuits that ultimately regulate brain activity and behavior.The National Institute of Neurological Disorders and Stroke (NINDS), in collaboration with the National Institute on Aging (NIA), National Institute of Mental Health (NIMH), National Institute on Drug Abuse (NIDA), and National Center for Advancing Translational Sciences (NCATS), convened a workshop to explore and evaluate the potential of a quantitative systems pharmacology (QSP) approach to CNS drug discovery and development. The objective of the workshop was to identify the challenges and opportunities of QSP as an approach to accelerate drug discovery and development in the field of CNS disorders. In particular, the workshop examined the potential for computational neuroscience to perform QSP‐based interrogation of the mechanism of action for CNS diseases, along with a more accurate and comprehensive method for evaluating drug effects and optimizing the design of clinical trials.Following up on an earlier white paper on the use of QSP in general disease mechanism of action and drug discovery, this report focuses on new applications, opportunities and the accompanying limitations of QSP as an approach to drug development in the CNS therapeutic area, based on the discussions in the workshop with various stakeholders.

Spatiotemporally resolved metabolomics and isotope tracing reveal CNS drug targets

In Silico Modeling on ADME Properties of Natural Products: Classification Models for Blood-Brain Barrier Permeability, Its Application to Traditional Chinese Medicine and in Vitro Experimental Validation

A new direction in metabolomics: Analysis of the central nervous system based on spatially resolved metabolomics

Whole-body Spatially-Resolved Metabolomics Method for Profiling the Metabolic Differences of Epimer Drug Candidates Using Ambient Mass Spectrometry Imaging.

Mapping Metabolic Networks in the Brain by Ambient Mass Spectrometry Imaging and Metabolomics

High-throughput brain activity mapping and machine learning as a foundation for systems neuropharmacology

Toward Drug Targets and Neuroimaging Biomarkers for Neuropsychiatric Disorders

Comprehensive quantitative method for neurotransmitters to study the activity of a sedative-hypnotic candidate using microdialysis and LC×LC-MS/MS

Mass spectrometry for biomarkers, disease mechanisms, and drug development in cerebrospinal fluid metabolomics

Ambient mass spectrometry imaging metabolomics method provides novel insights into the action mechanism of drug candidates.

High‐Density Optophysiology Platform for Recording Intracellular and Extracellular Signals Across the Brain of Free‐Moving Animals

An integrated microfluidic and fluorescence platform for probing in vivo neuropharmacology

Multi-Omics Integration Analysis Pinpoint Proteins Influencing Brain Structure and Function: Toward Drug Targets and Neuroimaging Biomarkers for Neuropsychiatric Disorders

Quantitative Systems Pharmacology for Neuroscience Drug Discovery and Development: Current Status, Opportunities, and Challenges

Predictors for drug effects with brain disease: Shed new light from EEG parameters to brain connectomics

Investigation of metabolic kinetics in different brain regions of awake rats using the [1H-13C]-NMR technique

Unraveling the drug distribution in brain enabled by MALDI MS imaging with laser-assisted chemical transfer

New perspective on central nervous system disorders: focus on mass spectrometry imaging

Mass Spectrometry-Based Quantitation Combined with Time-Dependent Metabolomics to Discover Metabolic Features in Human Neurogenesis Using Neural Constructs Generated from Neural Progenitor Cells.

Drug targets for cognitive enhancement in neuropsychiatric disorders

The Identification of Potential Anti-Depression/Anxiety Drug Targets by Stress-Induced Rat Brain Regional Proteome and Network Analyses